Vaginal Estradiol Seasonal Use Considerations

What the estradiol vaginal cream label covers

The cream is approved for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause [1]. The schedule is 2 to 4 g, marked on the applicator, daily for one or two weeks, then gradually reduced to one half the initial dosage for a similar period, with a maintenance dose of 1 g one to three times a week once the vaginal mucosa has been restored [1]. The label says use should be limited to the shortest duration consistent with treatment goals, with periodic reevaluation to decide whether treatment is still necessary [1]. The dosing section contains no step that depends on the season.

Vaginal tablets and rings are separate products with their own labeling, so the cream's schedule does not describe them.

Absorption and local reactions

The cream label states that systemic absorption may occur, and that the warnings, precautions and adverse reactions associated with oral estrogen treatment should be taken into account [1]. Among the listed reactions are application-site vulvovaginal discomfort including burning and irritation, and genital pruritus [1]. The same list includes vaginitis including vaginal candidiasis, and abnormal uterine bleeding or spotting [1].

Warnings and contraindications on the label

The boxed warning covers endometrial cancer, cardiovascular disorders, breast cancer and probable dementia, and the label advises the lowest effective dose for the shortest duration consistent with treatment goals [1]. Contraindications are undiagnosed abnormal genital bleeding; known, suspected or past breast cancer; known or suspected estrogen-dependent neoplasia; active DVT or PE or a history of these; active arterial thromboembolic disease or a history of it; known anaphylactic reaction or angioedema to the cream; known liver dysfunction or disease; known protein C, protein S or antithrombin deficiency or other thrombophilic disorders; and known or suspected pregnancy [1].

For undiagnosed persistent or recurring abnormal genital bleeding, the label calls for adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy [1].

What the tablet trial showed

A 2008 multicenter randomized trial assigned 230 postmenopausal women to 25 mcg or 10 mcg estradiol vaginal tablets or placebo for 12 weeks [2]. Both active doses significantly improved the composite vaginal health score (P<.001) and lowered vaginal pH more than placebo [2]. The 10 mcg and 25 mcg groups did not differ significantly on maturation value or the composite of three vaginal symptoms, although the authors concluded that improvements were greater with 25 mcg [2]. Efficacy with 25 mcg was maintained to week 52 in the open-label extension [2].

What the evidence does not address

The trial abstract reports no analysis by season, heat or travel, so the trial does not show whether seasonal conditions change how these products work.